Day 1 Program

Rapid Fire 2

Day 1: December 8, 2026

5:30 PM–6:30 PM CST

Stars at Night 1-2

Session Details

Moderator

Yara Abdou, University of North Carolina at Chapel Hill, Chapel Hill, NC

Moderator

David Rimm, Yale University School of Medicine, New Haven, CT

RF2-1

Updated Overall Survival (OS) Analysis from the Phase 3 ASCENT-07 Study of Sacituzumab Govitecan in Participants with HR+/HER2- Inoperable, Locally Advanced, or Metastatic Breast Cancer Post Endocrine Therapy

Hope S Rugo, City of Hope Comprehensive Cancer Center, Duarte, CA

RF2-2

Prognostic and predictive value of key immunohistochemistry (IHC) protein biomarker expression levels in the NATALEE trial of adjuvant ribociclib (RIB) and nonsteroidal aromatase inhibitor (NSAI) in hormone receptor-positive/human epidermal growth factor receptor 2−negative early breast cancer (HR+/HER2− EBC)

Michael Press, USC, Los Angeles, CA

RF2-3

h&E-derived gene-expression multimodal multitask modeling predicts chemotherapy benefit, distant recurrence risk, and 21-gene recurrence score in tailorx

Joseph Sparano, Icahn School of Medicine at Mount Sinai, New York, CA

RF2-4

Genomic Response-Guided Chemotherapy Omission After Neoadjuvant Ribociclib and Endocrine Therapy in High-Risk HR+/HER2− Early Breast Cancer: Updated Results from the Phase II SOLTI-UNICANCER RIBOLARIS Trial

Milana Arantza Bergamino Sirvén, Hospital Clinic de Barcelona// SOLTI// IDIBAPS, Barcelona, Spain

RF2-5

Prospective Validation of Modified PEPI Following Neoadjuvant (Neoadj) Anastrozole (ANA): Five-Year (5y) Recurrence-free Survival (RFS) from Alliance A011106 (ALTERNATE)

Cynthia X Ma, Washington University in St. Louis, Saint Louis, MO

RF2-6

Cdk2 mediates RB-independent entry into S phase and is a therapeutic target in ER+/RB-deficient, CDK4/6 inhibitor-resistant breast cancer

Chang-Ching A Lin, UT Southwestern Medical Center, Dallas, TX

RF2-7

Results from KEYNOTE-B49: a phase 3, randomized, double-blind study of pembrolizumab (vs placebo) plus chemotherapy in participants with HR+/HER2− locally recurrent inoperable or metastatic breast cancer

Peter Schmid, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom